Latest tuberculosis Stories
CAMBRIDGE, England, March 12, 2013 /PRNewswire/ -- ImmBio (Immunobiology Ltd), a biopharmaceutical company developing innovative vaccines against serious infectious diseases, today announced that the UK government-backed Biomedical Catalyst has awarded the company approximately GBP0.2 million ($0.3 million) to support pre-clinical development of its pneumococcal vaccine, PnuBioVax(TM), which targets a wide range of strains of the bacteria. This new grant follows the award of...
ZURICH-SCHLIEREN, Switzerland, March 6, 2013 /PRNewswire/ -- Following recently signed collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals, GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced that Gerd Zettlmeissl, will be appointed Chairman of the Board of Directors, effective June 2013, when Michel Greco steps down from the Chairmanship. Gerd Zettlmeissl has more than 20 years of experience in developing and...
Former Johnson & Johnson Chairman of Pharmaceuticals brings global product development and commercialization expertise NEW YORK, March 4, 2013 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization with the mission of developing better, faster-acting, and affordable TB treatments, announces the election to its Board of Directors of David Norton, former Company Group Chairman of Global Pharmaceuticals for Johnson & Johnson (J&J). Mr. Norton brings to TB...
Save $10 when ordering Tuberculosis testing from Request A Test. Early diagnosis through lab testing is the key to keeping this infectious disease from spreading. Offer expires 3/31/13. Brecksville, OH (PRWEB) March 01, 2013 This March, Request A Test, a leading national provider of direct to consumer lab testing, is offering $10 off of lab testing for Tuberculosis. To take advantage of this discount, patients just need to use promo code TBTEST10 when placing their order. Many Americans...
WALTHAM, Mass., March 1, 2013 /PRNewswire/ -- Alere Inc. (NYSE: ALR) announced today that it has been awarded a grant of up to $21.6 million and debt financing of up to $20.6 million from the Bill & Melinda Gates Foundation. The $21.6 million grant will fund the development of a tuberculosis assay, which will be designed for use in both resource-constrained and well-resourced settings. It will also support the company's efforts to incorporate one of its isothermal amplification...
Up to $1.9 billion Available in 2013 and 2014 GENEVA, Feb. 28, 2013 /PRNewswire/ -- The Global Fund to Fight AIDS, Tuberculosis and Malaria today launched a new funding model that allows it to invest more strategically, achieve greater impact, and engage implementers and partners more effectively. The new funding model provides countries that implement grants with more flexibility around when they apply for funds, as well as more predictability on the level of funding...
Designed to help improve consistency and reliability of intradermal injections EXTON, Pa., Feb. 27, 2013 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading global developer and manufacturer of components and systems for injectable drug delivery, announces the commercial introduction of its ID Adapter. West acquired a license to the technology in 2010 and has completed the product development and first phase of commercial scale-up at its manufacturing center in...
Global health expert and diplomat to lend skills, support to optimize new TB drug introductions WASHINGTON and NEW YORK, Feb. 25, 2013 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization with the mission of developing new, improved, and affordable TB treatments, announces the election of Karl Hofmann, President and CEO of Population Services International (PSI), as President of the TB Alliance's Stakeholders Association (SHA), thereby assuming a seat on its Board...
Special edition to mark World TB day maps new issues and approaches to curbing spread of infection During the 1930s, dedicated sanitaria and invasive surgery were commonly prescribed for those with the infection - usually caused by Mycobacterium tuberculosis, which the editors describe as "the most successful human pathogen of all time." TB often lies dormant with no symptoms, but in a proportion of cases, becomes active, predominantly attacking the lungs. But it can also affect the...
[ Watch the Video: Discussing New Tuberculosis Vaccine Trials ] Lee Rannals for redOrbit.com - Your Universe Online A new vaccine considered to be the most advanced for tuberculosis (TB) among more than a dozen now in trials has failed its study. Researchers said they were disappointed by the results of the study, which showed that the vaccine offered little to no protection at all from TB. Nearly 3,000 babies in South Africa took part in the study, all of whom had already been...
Latest tuberculosis Reference Libraries
Mycobacterium tuberculosis (MTB) is a pathogenic bacterial species in the genus Mycobacterium and the causative agent of most cases of tuberculosis. Robert Koch first discovered it in 1882 and that it had an unusual, waxy coating on the cell surface which makes them impossible to Gram stain. M. tuberculosis is highly aerobic and requires high levels of oxygen. It generally infects the respiratory system of mammals. Tuberculin skin test, acid-fast stain, and chest radiographs are the most...
Mycobacterium bovis is a slow-growing, aerobic bacterium and the causative agent of tuberculosis in cattle. Similar to M. tuberculosis, M. bovis can jump the species barrier and cause tuberculosis in humans. It is estimated that M. bovis was responsible for more losses among farm animals than all other diseases combined in the first half of the 20th century. Infection happens after bacterium is ingested. It is generally transmitted to humans via infected milk. Actual human infections are...
